Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals Stock Pops; Imcivree Gets Approval Where GLP-1s Have 'Fallen Flat' | Investor's Business Daily MUTUAL FUNDS: How Top Funds Deliver Market-Beating Returns Rhythm Pharmaceuticals (RYTM) stock popped Friday after the Food and Drug Administration signed off on its obesity drug for patients with a rare, hunger-spiking disease. The company's Imcivree already has approval for a pool of roughly 7,500 patients in the U.S. with genetically driven forms of obesity. Now, the new approval in patie ...